(Reuters) - LONDON, June 21 - Shire Plc said on Thursday the U.S. Food and Drug Administration intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit hyperactivity disorder .
Britain's third-biggest drugmaker said it had received an "approvable letter" from the U.S. medicines regulator for Intuniv, formerly known as Connexyn, signaling it will approve a new drug pending further information.
Read more at Reuters.com Government Filings News
Britain's third-biggest drugmaker said it had received an "approvable letter" from the U.S. medicines regulator for Intuniv, formerly known as Connexyn, signaling it will approve a new drug pending further information.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment